PRGN-3005

N/A

Report date: 2022/07/04 19:38:02

Base Information

Drug NamePRGN-3005
Drug Alias NamePRGN-3005
ClassificationCell and gene therapy > Gene therapyCell and gene therapy > Cell therapy > Immune system cell therapy > Lymphocytes therapy > T-lymphocyte cell therapy > Chimeric antigen receptor T cell therapy
Mechanisms of ActionImmunologic cytotoxicityT lymphocyte replacementsMucin-16 inhibitors
TargetsMucin-16
Therapy Area/IndicationsUterine Cervical NeoplasmsFallopian Tube NeoplasmsOvarian Neoplasms +[7] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryUnited States
CombinationsNo
Global Highest StatusPhase 1 Clinical
Highest Status in ChinaN/A
Originator CompaniesPrecigen Inc
China Registration ClassN/A

Develop Information

Active CompaniesPrecigen Inc
Inactive CompaniesN/A
Active IndicationsUterine Cervical NeoplasmsFallopian Tube NeoplasmsOvarian Neoplasms +[7] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A